Ueda et al. (2017) revealed by immunohistochemical analysis that NHE9 is up-regulated in CRC compared to normal tissue. NHE9 is closely related to EGFR (EGF receptor) signaling pathways. Its overexpression promotes the progression and the metastatic potential of CRC and, thus, may be a prognostic marker and a potential therapeutic target (Ueda et al., 2017). The gene discussed is EGFR; the disease is colorectal carcinoma.